home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


Mar6Capital Royalty Enhances Royalty Investment Team With New Principals Weinmann and Düster

Houston, TX - March 6, 2009 – Capital Royalty L.P. (“Capital Royalty”) announced today that Mike Weinmann and Luke Düster have joined Capital Royalty as Principals of the Firm, significantly enhancing its royalty bond financing and business development capabilities. In conjunction with Mr. Weinmann’s appointment, Capital Royalty will open a New York, New York office to be led by Mr. Weinmann. Mr. Düster joins Nate Hukill in managing the Firm’s recently-opened Boulder, Colorado office. 


Mr. Weinmann brings a decade of capital markets experience and is responsible for $35 billion in completed financing transactions, including $3.3 billion in pharmaceutical royalty transactions. As Executive Director of Morgan Stanley’s Global Capital Markets Division, Mr. Weinmann specialized in structured debt financings and intellectual property monetizations. He is the co-developer of biopharmaceutical royalty bonds and marketed the first 14 royalty bond transactions, raising more than $1.8 billion in capital. 


Mr. Düster brings over ten years of experience transacting mergers and acquisitions, most recently as Vice President of Harris Williams & Co., where he co-founded the firm’s Philadelphia office, spearheaded its business development efforts, and advised private equity and corporate clients across a broad spectrum of industries.  He has held investment banking roles at The Wallach Company, a regional investment banking boutique, and at the Nord Companies, a healthcare-focused advisory firm.


“Our stated goal is to strengthen and position Capital Royalty for market leadership in healthcare investing for the future. Our plan is three-fold: assemble a world-class investment team that unites the finest pioneers and innovators in healthcare financing; sharpen our collective vision to enhance our competitive market advantage; and, refine our royalty investment strategy to attract the highest-quality IP assets through the design of innovative royalty financing structures,” said Charles W. Tate, Capital Royalty Founder and Chairman.


“With the addition of Mike Weinmann and the recent appointment of Nate Hukill as Managing Director, Capital Royalty has attracted the industry’s two founders and innovators of the royalty-backed bond structure – a pioneering financing instrument able to deliver superior risk-adjusted returns with greater downside protection than traditional direct purchases of royalty interests. The addition of Mr. Düster significantly enhances the Firm’s expertise in sourcing, lead generation and business development initiatives.  Today’s Capital Royalty team represents the finest experts across the spectrum of healthcare royalty monetization, including biopharmaceutical royalty bonds, traditional royalty purchases and other healthcare royalty-related investments,” said Mr. Tate.


In conjunction with Mr. Weinmann’s appointment, Capital Royalty also announced the opening of its New York, New York office.  “The New York office will provide easier access to East Coast biopharmaceutical hubs in New York, New Jersey and Massachusetts while facilitating our efforts to build stronger relationships with key institutional investors and capital sources in New York. Together with our recently opened Boulder office and Houston headquarters, Capital Royalty has established a truly national market presence that allows us to strengthen our connections among royalty holders,” Mr. Tate concluded.



Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bond and other royalty monetization structures. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors. The Firm is headquartered in Houston, Texas with offices in New York, New York and Boulder, Colorado. For further information, please visit www.capitalroyalty.com.